DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer MINNEAPOLIS, April 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of Mr. Scott Kellen as Chief Financial...

DiaMedica Therapeutics Announces Final Closing of Private Placement MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second...

DiaMedica Therapeutics Announces Closing of Private Placement MINNEAPOLIS, March 20, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the first closing of a...

DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke DM199 may offer an effective and safe treatment with a significantly longer treatment window (24 hours) compared to the current standard of careREMEDY trial lead by prominent neurologist Dr. Bruce...

DiaMedica to Present at the 14th Annual Noble Investor Conference MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital...